Di Zenzo G, Carrozzo M, Chan L S
Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
Oral Dis. 2014 Jan;20(1):35-54. doi: 10.1111/odi.12193. Epub 2013 Nov 6.
Mucous membrane pemphigoid (MMP) is a heterogeneous group of autoimmune subepithelial blistering diseases affecting primarily mucous membranes showing marked degree of clinical and immunological variability. We investigated four controversial topics: (i) Does oral pemphigoid (OP) really exist as a separate entity? (ii) Is mucous membrane pemphigoid curable? (iii) What is the best therapeutic option for MMP? (iv) Does exclusive oral IgA dermatitis exist as a distinct entity from MMP? Results from extensive literature searches suggested that (i) it is still unclear whether patients with OP could be considered as a distinct subset of MMP with specific clinical and immunological features; (ii) it is uncertain whether treatment regimens that get MMP under control can be eliminated to allow patients to be in drug-free remission or they should be continuously administered in some capacities; (iii) there is a concerning paucity of good-quality trials on MMP and available recommendations are solely based on generally small patients' cohorts or case series. Some of the 2002 consensus experts' opinions should be possibly updated, particularly regarding the safety of sulfa drugs; (iv) we did not find any strong evidence to support an exclusive oral (and perhaps also mucosal) form of LAD as a separate entity.
黏膜类天疱疮(MMP)是一组异质性自身免疫性上皮下疱病,主要累及黏膜,在临床和免疫学方面表现出显著的变异性。我们研究了四个有争议的话题:(i)口腔类天疱疮(OP)是否真的作为一个独立的实体存在?(ii)黏膜类天疱疮能否治愈?(iii)MMP的最佳治疗选择是什么?(iv)单纯口腔IgA皮炎是否作为一种与MMP不同的独特实体存在?广泛文献检索的结果表明:(i)尚不清楚OP患者是否可被视为具有特定临床和免疫学特征的MMP的一个独特亚组;(ii)不确定控制MMP的治疗方案是否可以停用,以使患者处于无药缓解状态,还是应以某种方式持续给药;(iii)关于MMP的高质量试验非常匮乏,现有建议仅基于一般规模较小的患者队列或病例系列。2002年共识专家的一些意见可能需要更新,特别是关于磺胺类药物的安全性;(iv)我们没有发现任何有力证据支持单纯口腔(可能还有黏膜)形式的线状IgA大疱性皮病作为一个独立实体存在。